Finepoint Capital LP Buys Shares of 660,000 Xencor, Inc. (NASDAQ:XNCR)

Finepoint Capital LP bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 660,000 shares of the biopharmaceutical company's stock, valued at approximately $15,167,000. Xencor comprises 0.9% of Finepoint Capital LP's portfolio, making the stock its 11th biggest holding. Finepoint Capital LP owned approximately 0.94% of Xencor as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of XNCR. Vanguard Group Inc. grew its holdings in Xencor by 5.5% in the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after purchasing an additional 418,040 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Xencor by 12.3% in the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock valued at $37,578,000 after purchasing an additional 179,526 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Xencor by 21.3% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock valued at $25,102,000 after buying an additional 192,080 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Xencor by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 630,640 shares of the biopharmaceutical company's stock worth $14,492,000 after buying an additional 3,652 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Xencor by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 437,152 shares of the biopharmaceutical company's stock valued at $10,046,000 after acquiring an additional 18,586 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on XNCR shares. Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. StockNews.com downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.38.

Xencor Stock Down 1.0 %

Shares of XNCR traded down $0.08 during mid-day trading on Friday, reaching $7.84. 242,232 shares of the stock traded hands, compared to its average volume of 611,885. The firm has a market cap of $552.42 million, a price-to-earnings ratio of -2.45 and a beta of 0.90. The stock has a fifty day simple moving average of $13.26 and a 200 day simple moving average of $19.17. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.